


Product Name : Orelabrutinib
Cat. No. : PC-23189
CAS No. : 1655504-04-3
Molecular Formula : C₂₆H₂₅N₃O₃
Molecular Weight : 427.50
Target : BTK
Solubility : 10 mM in DMSO



Biological Activity

Orelabrutinib (ICP-022) is a potent, selective, orally active, and irreversible Bruton's tyrosine kinase (**BTK**) inhibitor with IC₅₀ of 1.6 nM.

Orelabrutinib (ICP-022) displays high selectivity at 1 μM against a panel of 456 kinases, only targets BTK with >90% inhibition lacking inhibition on many additional kinases, including EGFR, TEC, and bone marrow tyrosine kinase.

Orelabrutinib (ICP-022) inhibited B cell lymphoma cell proliferation in vitro (TMD8 cell, IC₅₀=0.08 μM).

Orelabrutinib (ICP-022) lacked inhibition on cellular ITK compared with ibrutinib.

Orelabrutinib (ICP-022) preserved rituximab-mediated cytotoxicity, the combination of orelabrutinib and rituximab treatment enhanced NK-cell-mediated ADCC.

Orelabrutinib (ICP-022) combined with rituximab effectively inhibited tumor growth in animal models.

References

Yu H, et al. *Mol Ther Oncolytics*. 2021 Apr 3;21:158-170.

Wu JJ, et al. *Invest New Drugs*. 2022 Jun;40(3):650-659.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com